Patent · US Active

Inhibitors of CCR9 activity

US7759390B2 · kind B2 · utility

1Cited by

0References

4Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Jose M. Carballido Herrera · Allschwil, CH
Herbert Jaksche · Wien, AT
Philipp Lehr · Spittal an der Drau, AT
Gudrun Werner · Wien, AT
Anthony Winiski · Wien, AT

Key dates

Filing date	Dec 22, 2006
Grant date	Jul 20, 2010
Priority date	—
Expiry date	Dec 22, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula I, wherein one of R1 and R2 is thienyl which is substituted by halogen and the other of R1 and R2 is substituted phenyl, wherein the substituents are as defined in the claims, with the proviso that the phenyl group is substituted by at least a cyano, carboxy or (C1-4)alkyloxycarbonyl group, are inhibitors of CCR9 activity and useful for therapeutic treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.